ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2008
Assessing response to osteoporosis therapy.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Moroccan national guidelines for the management of postmenopausal osteoporosis.Archives of osteoporosis · 2026Guideline
- Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Pooled it
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2010Guideline
- Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues.Therapeutic advances in musculoskeletal disease · 2022Review
- Bone mineral density response prediction following osteoporosis treatment using machine learning to aid personalized therapy.Scientific reports · 2021Article
- Operationalizing Treat-to-Target for Osteoporosis.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- Investigation of Pyrophosphates KYPNanomaterials (Basel, Switzerland) · 2019Article
- Osteoporosis: Treat-to-Target.Current osteoporosis reports · 2017Review
- Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis.Osteoporosis and sarcopenia · 2016Review
- The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey.Journal of bone and mineral metabolism · 2015Article
- Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Observational
- Characteristics associated with bone mineral density responses to alendronate in men.Calcified tissue international · 2013Article
- Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.Journal of bone and mineral metabolism · 2012Article
- Bone densitometry and vertebral fracture assessment.Current osteoporosis reports · 2010Review
- Bisphosphonates for the treatment of osteoporosis: insights for clinicians.Therapeutic advances in chronic disease · 2010Article
- Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis.Current osteoporosis reports · 2010Review
- Management of osteoporosis in central and eastern Europe (CEE): conclusions of the "2nd Summit on Osteoporosis-CEE", 21-22 November 2008, Warsaw, Poland.Archives of osteoporosis · 2009Article
- Prevention of osteoporosis-related fractures among postmenopausal women and older men.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Review
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsArticle
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients treated with pharmacological agents to improve bone strength and reduce fracture risk may not achieve optimal skeletal benefit for reasons that include poor compliance and persistence, inadequate calcium and vitamin D intake, malabsorption, and medications or co-morbidities with adverse skeletal effects. Monitoring the effects of therapy can inform the patient and physician that the drug is having its expected skeletal response. Treatment is often monitored with serial bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry or bone turnover markers (BTMs). Stable or increasing BMD is associated with reduced fracture risk in clinical trials, and is considered an indication of good response to therapy in individual patients outside of clinical trials. There are many differences between subjects in clinical trials and patients being treated in clinical practice. Thus, although defining a clinical practice patient as a "nonresponder" or "suboptimal responder" to treatment is problematic, a pragmatic approach would be to consider evaluation for contributing factors and possible changes in therapy in patients who have a statistically significant decrease in BMD, do not have the expected change in BTMs, or have a fracture.
Indexed as
Identifiers
18546030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.